SAN
DIEGO, Sept. 19, 2024 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen
4th Annual Novel Mechanisms in Neuropsychiatry Virtual
Summit at 11:00 a.m. Eastern Time on
Thursday, September 26, 2024. Chief Business Development and
Strategy Officer and CEO-elect Kyle
Gano and Vice-President of Investor Relations Todd Tushla will present at the conference.
The live presentation will be webcast and may be accessed on
Neurocrine Biosciences' website under Investors at
www.neurocrine.com. A replay of the webcast will be available on
the website approximately one hour after the conclusion of the
event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is
a leading neuroscience-focused, biopharmaceutical company with a
simple purpose: to relieve suffering for people with great needs,
but few options. We are dedicated to discovering and developing
life-changing treatments for patients with under-addressed
neurological, neuroendocrine, and neuropsychiatric disorders.
The company's diverse portfolio includes FDA-approved treatments
for tardive dyskinesia, chorea associated with Huntington's
disease, endometriosis* and uterine fibroids*, as well as a robust
pipeline including multiple compounds in mid- to late-phase
clinical development across our core therapeutic areas. For three
decades, we have applied our unique insight into neuroscience and
the interconnections between brain and body systems to treat
complex conditions. We relentlessly pursue medicines to ease the
burden of debilitating diseases and disorders, because you deserve
brave science. For more information, visit neurocrine.com, and
follow the company on LinkedIn, X (Formerly Twitter) and Facebook.
(*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE
SCIENCE are registered trademarks of Neurocrine Biosciences,
Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-the-td-cowen-4th-annual-novel-mechanisms-in-neuropsychiatry-virtual-summit-302253660.html
SOURCE Neurocrine Biosciences, Inc.